Human PD1

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only (RUO). NonTherapeutic.

28°C Wet Ice

This nontherapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD1 and does not bind to other IgG superfamily proteins. This product is for research use only.

Programmed cell death protein 1 (PD1) is a protein on the surface of cells that plays a role in the maintenance of selftolerance. PD1 promotes selftolerance via the downregulation of the immune system which results in the suppression of T cell inflammatory activity. PDL1 and PDL2 are the two ligands known to bind PD1. PDL1 has increased expression in several cancers.¹ PDL2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro Tcell responses and via the mediation of antitumor activity.² Nivolumab disrupts the negative signal that is responsible for Tcell activation and proliferation by binding to PD1 on activated immune cells to selectively block the interaction of the PD1 receptor with its ligands.³ Emerging research suggests that combined blockade of PD1 and CTLA4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.⁴ This costeffective, researchgrade AntiHuman CD279 (PD1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.

PD1 is expressed on a subset of CD4CD8 thymocytes, and on activated T and B cells.

PDL1 and PDL2

1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293–97.
2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):84656.
3. Li, Y. et al. (2016) MAbs. 8(5):95160.
4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):12233.